Synonym
Bucloxic acid calcium salt; CB 804 calcium; Calcium esfar; Bucloxic acid calcium;
IUPAC/Chemical Name
calcium 4-(3-chloro-4-cyclohexylphenyl)-4-oxobutanoate
InChi Key
FKJKZQUQHXSBHB-UHFFFAOYSA-L
InChi Code
InChI=1S/2C16H19ClO3.Ca/c2*17-14-10-12(15(18)8-9-16(19)20)6-7-13(14)11-4-2-1-3-5-11;/h2*6-7,10-11H,1-5,8-9H2,(H,19,20);/q;;+2/p-2
SMILES Code
O=C([O-])CCC(C1=CC=C(C2CCCCC2)C(Cl)=C1)=O.O=C([O-])CCC(C3=CC=C(C4CCCCC4)C(Cl)=C3)=O.[Ca+2]
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
627.61
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Magous R, Bali JP, Escale R, Girard JP, Rechencq E, Rossi JC. Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets. Mol Pharmacol. 1986 Jan;29(1):39-44. PubMed PMID: 3945226.
2: Paolaggi JB. [New non-steroidal anti-inflammatory agents]. Rev Prat. 1980 Apr 21;30(23):1525-30, 1533. French. PubMed PMID: 7189898.
3: Deidier CM, Schuhl JF. [Bucloxic acid in plastic surgery]. Ann Chir Plast. 1975;20(3-4):343-5. French. PubMed PMID: 1211844.
4: Lagrue G, Masbernard A, Giudicelli C, Hirbec G. Use of a new anti-inflammatory agent, bucloxic acid, in the treatment of chronic glomerular nephropathies. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1434-9. PubMed PMID: 4614821.
5: Mazué G, Vindel JA, Landsmann F, Brunaud M. Study of possible mutagenicity of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1422-5. PubMed PMID: 4614818.
6: Mazué G, Landsmann F, Brunaud M. Study of possible teratogenicity of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1413-22. PubMed PMID: 4480071.
7: Mazué G, Vallée E, Genet P, Navarro J, Brunaud M. Toxicological studies of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1398-413. PubMed PMID: 4480070.
8: Chasseaud LF, Fry BJ, Gros PM. Metabolic and pharmacokinetic study of bucloxic acid. II. Pharmacokinetic study in the baboon. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1390-7. PubMed PMID: 4480069.
9: Gros PM, Davi HJ, Chasseaud LF, Hawkins DR. Metabolic and pharmacokinetic study of bucloxic acid. I. Isolation and identification of the main excretion products in animals and in man. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1385-90. PubMed PMID: 4480068.
10: Navarro J, Stoliaroff M, Savy JM, Berny C, Brunaud M. [Pharmacologic properties of a new, nonsteroidal anti-inflammatory agent, bucloxic acid (804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1368-78. French. PubMed PMID: 4480066.
11: Krausz F, Breliere JC, Vaillant J, Brunaud M, Navarro J. [A new nonsteroidal anti-inflammatory agent: bucloxic acid (804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1364-7. French. PubMed PMID: 4480065.
12: Brunard M. [Introduction: Esfar (bucloxic acid, 804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1359. French. PubMed PMID: 4480063.
